HHLR ADVISORS, LTD.
Institutional investor · Portfolio as of Q1 2026
SEC EDGAR SourceSEC Filings
HHLR ADVISORS, LTD. manages $1.7B across 38 positions as of Q1 2026. Top holdings: PDD (25.4%), BABA (18.4%), ONC (18.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Q1 2026 Summary
Active quarter - 9 new positions, 4 exits, 2 increased. Top move: MRVL (NEW, conviction 65). Portfolio: $1.7B across 38 positions.
Top holdings by portfolio weight
PDD25.44%
BABA18.40%
ONC18.36%
FUTU11.60%
LEGN6.47%
AVBP5.42%
BEKE3.79%
CWAN1.93%
CTKB1.74%
MRVL1.01%
Other0.90%
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Upgrade to Pro to see the worst-performing positions.
View plansCost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Top Holdings38 positions
Activity:
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction | |
|---|---|---|---|---|---|---|---|---|
PDD HOLDINGS INC | 4.2M | $425.6M | 25.4% | $114.13 | -16.04% | 16 qtrssince 2022-Q2 | Decreased 0 | |
ALIBABA GROUP HLDG LTD | 2.5M | $307.8M | 18.4% | $146.94 | -9.77% | 16 qtrssince 2022-Q2 | Decreased 0 | |
BEONE MEDICINES LTD | 1M | $307.2M | 18.4% | $134.02 | +118.82% | 30 qtrssince 2018-Q4 | Unchanged 0 | |
FUTU HLDGS LTD | 1.4M | $194.1M | 11.6% | $95.17 | +41.48% | 8 qtrssince 2024-Q2 | Decreased 0 | |
LEGEND BIOTECH CORP ADR | 6M | $108.3M | 6.5% | $50.33 | -45.26% | 24 qtrssince 2020-Q2 | Unchanged 0 | |
ARRIVENT BIOPHARMA INC | 3.9M | $90.6M | 5.4% | $17.95 | +55.30% | 9 qtrssince 2024-Q1 | Unchanged 0 | |
KE HLDGS INC | 4.2M | $63.4M | 3.8% | $21.74 | -16.41% | 23 qtrssince 2020-Q3 | Unchanged 0 | |
CLEARWATER ANALYTICS HLDGS I | 1.4M | $32.3M | 1.9% | $22.00 | +10.68% | 4 qtrssince 2025-Q2 | Unchanged 0 | |
CYTEK BIOSCIENCES INC | 6.7M | $29.1M | 1.7% | $20.96 | -83.78% | 19 qtrssince 2021-Q3 | Unchanged 0 | |
MARVELL TECHNOLOGY INC | 171,033 | $16.9M | 1.0% | $77.51 | +128.22% | 1 qtr | New 65 | |
Showing 10 of 38 results.28 more with Pro.PROUpgrade to see all → | ||||||||
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer